Sirtex Medical Limited (SRXH) Stock Analysis & DCF Valuation

Sirtex Medical Limited logo

SRXH · NASDAQ ·

Buy

High confidence

Sirtex Medical develops and commercializes targeted radiation therapies for liver cancer. Trading on the NASDAQ, the stock faces integration challenges post-acquisition.

Sirtex Medical Limited Intrinsic Value & DCF Valuation

Our discounted cash flow (DCF) model estimates Sirtex Medical Limited fair value at $NaN per share, compared to the current market price of $NaN. This implies +105259.1% upside from today's price.

Fair Value (DCF) $NaN
Current Market Price $NaN
Upside / Downside +105259.1%

SRXH Key Financial Metrics

Market Cap $175.58 Million
P/E Ratio N/A
Dividend Yield 0.00%
Analyst Target Price $5.00

Sirtex Medical Limited Long-Term Stock Outlook

Long-term outlook depends heavily on the success of expanding SIR-Spheres use globally and successful commercialization of any next-generation oncology devices in the pipeline.

Bullish Factors

  • [object Object]
  • [object Object]
  • [object Object]

Key Risks

  • [object Object]
  • [object Object]
  • [object Object]

SRXH Analyst Sentiment & Market Consensus

Analyst sentiment appears moderately positive, supported by a $5.00 target price suggesting modest upside from recent trading levels, though coverage is light.

Should You Buy SRXH Stock?

Recommendation: Buy High confidence

No recommendation provided

Frequently Asked Questions

Is SRXH a good stock to buy?

Based on our AI analysis, Sirtex Medical Limited (SRXH) is rated as Buy with high confidence. Sirtex Medical develops and commercializes targeted radiation therapies for liver cancer. Trading on the NASDAQ, the stock faces integration challenges post-acquisition.

What is SRXH stock price target?

Our DCF valuation model estimates Sirtex Medical Limited (SRXH) fair value at $NaN, suggesting +105259.1% downside potential from current price of $NaN.

What is SRXH fair value?

The fair value for Sirtex Medical Limited (SRXH) is estimated at $NaN based on discounted cash flow (DCF) analysis. This represents +105259.1% downside from the current price.

*This analysis is for informational purposes only and should not be taken as financial advice.*

© 2025 stockpickr - AI-Powered Stock Analysis

View more stock analyses